Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
Create a narrative
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Novo Nordisk
BA
bactrian
Community Contributor
A Quality Compounder Marked Down on Overblown Fears
Novo Nordisk , a global leader in diabetes and obesity treatments, is trading at a deep discount to both its historical multiples and intrinsic value. The ADR is now priced at $47.05 , reflecting a normalized P/E ratio of just 13.4× , down from a five-year average closer to 25–30×.
View narrative
US$120.72
FV
60.9% undervalued
intrinsic discount
15.71%
Revenue growth p.a.
Set Fair Value
16
users have liked this narrative
4
users have commented on this narrative
33
users have followed this narrative
New
narrative
ASML Holding
IN
Investingwilly
Community Contributor
Why Now is the Time to buy ASML
What Does ASML Do? ASML Holding N.V. is a Dutch company and the world’s only supplier of extreme ultraviolet (EUV) lithography machines —a critical technology used to produce the world’s most advanced computer chips.
View narrative
US$1.00k
FV
31.0% undervalued
intrinsic discount
15.17%
Revenue growth p.a.
Set Fair Value
20
users have liked this narrative
3
users have commented on this narrative
45
users have followed this narrative
New
narrative
Wyndham Hotels & Resorts
ZW
Zwfis
Community Contributor
Wyndham Continues Global Expansion with 19% Ancillary Revenue Growth
WH is a company that I actually took interest in a couple of months ago when I happened to stay at one of their franchise hotels. I had to leave early in the morning at like 4 and when I went out to the parking lot I was astounded that in the little town I was was absolutely full.
View narrative
US$105.80
FV
19.7% undervalued
intrinsic discount
13.23%
Revenue growth p.a.
Set Fair Value
4
users have liked this narrative
1
users have commented on this narrative
6
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Definitive Healthcare
AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts
Improved Data Integration And Healthcare Partnerships Will Create Value
Key Takeaways Enhancing data integration and customer retention efforts is expected to boost customer relationships, stabilize churn rates, and positively impact revenue and margins. Strategic partnerships and differentiated data services are set to broaden market reach, capture new clients, and drive long-term earnings growth, especially in life sciences.
View narrative
US$4.10
FV
5.4% undervalued
intrinsic discount
-1.07%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
13 days ago
author updated this narrative
Evolv Technologies Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
AI Screening Will Expand Public Safety Applications
Key Takeaways Heightened demand for advanced security and regulatory mandates drive strong growth potential for recurring subscription revenue across diverse markets. Transition to a subscription model increases earnings visibility and profitability, supported by high customer retention and expanding existing accounts.
View narrative
US$7.06
FV
1.2% overvalued
intrinsic discount
17.56%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
13 days ago
author updated this narrative
Digimarc
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
US Gift Card Protection Will Improve Security While Facing Challenges
Key Takeaways Strategic focus on high-growth areas and divestment of non-core operations could soon lead to sustainable free cash flow. Anticipated partnerships and customer advocacy may enhance revenue streams and boost earnings stability.
View narrative
US$22.50
FV
46.6% undervalued
intrinsic discount
-2.85%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
13 days ago
author updated this narrative
Centerspace
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
Midwest And Mountain West Demand Will Secure Future Success
Key Takeaways Strong demand in key regions and a decrease in new apartment supply bolster revenue growth through improved leasing and occupancy rates. Robust financial positioning and favorable macro conditions support strategic acquisitions and steady revenue growth through effective capital allocation.
View narrative
US$70.05
FV
23.0% undervalued
intrinsic discount
3.58%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
13 days ago
author updated this narrative
TechTarget
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
AI And Cybersecurity Trends Will Drive Global Market Expansion
Key Takeaways TechTarget is leveraging AI, cloud, and data trends to boost demand for specialized content, lead generation, and high-margin, intent-driven marketing solutions. Operational efficiency, strategic international growth, and proprietary data investments are improving client retention, upselling, and supporting sustainable market share gains.
View narrative
US$12.33
FV
45.8% undervalued
intrinsic discount
29.50%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
13 days ago
author updated this narrative
Xencor
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
IBD Biologics And TL1A Programs Will Forge New Paths
Key Takeaways Differentiated drug design and flexible development platform position Xencor for increased patient adoption, operational efficiency, and attractive long-term profitability. Strong clinical strategy and alignment with healthcare trends support sustained market expansion and robust future revenue growth.
View narrative
US$28.20
FV
71.8% undervalued
intrinsic discount
14.60%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
13 days ago
author updated this narrative
Arrowhead Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 14 Analysts
Plozasiran Launch Will Transition Biotech Focus Despite Regulatory Hurdles
Key Takeaways Transition to a commercial stage with plozasiran could significantly boost future revenues and improve margins through successful product launches. Early-stage obesity programs targeting new treatment pathways may create significant new revenue streams and enhance long-term growth.
View narrative
US$44.00
FV
62.6% undervalued
intrinsic discount
-13.45%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
13 days ago
author updated this narrative
Lumen Technologies
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
Private Connectivity Buildout Will Expand Digital Services Despite Legacy Headwinds
Key Takeaways Expansion of private connectivity, digital platforms, and fiber services is driving growth, new recurring revenues, and higher margins through enterprise and AI-driven demand. Cost-saving modernization, legacy migration, and improved financial flexibility are supporting earnings, margin expansion, and future investment in core digital infrastructure.
View narrative
US$4.90
FV
23.5% undervalued
intrinsic discount
-4.63%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
48
users have followed this narrative
13 days ago
author updated this narrative
Tempus AI
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
AstraZeneca And Pathos Partnership Will Expand Precision Medicine
Key Takeaways Pharma partnerships and the shift toward AI-driven precision medicine are fueling strong, high-margin revenue growth and expanding Tempus' competitive opportunities. Integration of new platforms and data assets strengthens product differentiation, increases client retention, and accelerates the shift to high-margin software and data contracts.
View narrative
US$66.77
FV
13.5% undervalued
intrinsic discount
37.30%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
95
users have followed this narrative
13 days ago
author updated this narrative
Value any company in seconds
Popular companies